These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 33428718)
1. Aldosterone receptor antagonism in patients with diabetes and chronic kidney disease: new promises and old problems. Patrono C; Volpe M Eur Heart J; 2021 Jan; 42(1):14-15. PubMed ID: 33428718 [No Abstract] [Full Text] [Related]
2. Letter to the Editor: Finerenone: A New Era for Mineralocorticoid Receptor Antagonism and Cardiorenal Protection. Ahmed M; Abbas J; Imtiaz H Curr Probl Cardiol; 2024 Jan; 49(1 Pt B):102067. PubMed ID: 37678423 [No Abstract] [Full Text] [Related]
3. [Antifibrotic renal role of mineralcorticoid receptor antagonists]. Ocello A; La Rosa S; Fiorini F; Randone S; Maccarrone R; Battaglia G; Granata A G Ital Nefrol; 2019 Jul; 36(4):. PubMed ID: 31373464 [TBL] [Abstract][Full Text] [Related]
4. Finerenone (Kerendia) for chronic kidney disease. Med Lett Drugs Ther; 2021 Aug; 63(1631):131-132. PubMed ID: 34544101 [No Abstract] [Full Text] [Related]
5. Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD? Haller H; Bertram A; Stahl K; Menne J Curr Hypertens Rep; 2016 Apr; 18(5):41. PubMed ID: 27115525 [TBL] [Abstract][Full Text] [Related]
9. [Finerenone in patients with chronic kidney disease and type 2 diabetes mellitus]. Wanner C; Nitschmann S Internist (Berl); 2021 May; 62(5):577-580. PubMed ID: 33877367 [No Abstract] [Full Text] [Related]
10. Aldosterone receptor antagonists: current perspectives and therapies. Guichard JL; Clark D; Calhoun DA; Ahmed MI Vasc Health Risk Manag; 2013; 9():321-31. PubMed ID: 23836977 [TBL] [Abstract][Full Text] [Related]
11. New pharmacological strategies for protecting kidney function in type 2 diabetes. Muskiet MHA; Wheeler DC; Heerspink HJL Lancet Diabetes Endocrinol; 2019 May; 7(5):397-412. PubMed ID: 30579729 [TBL] [Abstract][Full Text] [Related]
12. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B; Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733 [TBL] [Abstract][Full Text] [Related]
13. Finerenone: A Non-steroidal Mineralocorticoid Receptor Blocker for Diabetic Kidney Disease. Verma A; Patel AB Trends Endocrinol Metab; 2021 May; 32(5):261-263. PubMed ID: 33637415 [TBL] [Abstract][Full Text] [Related]
14. Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism. Epstein M Lancet Diabetes Endocrinol; 2015 Dec; 3(12):993-1003. PubMed ID: 26429402 [TBL] [Abstract][Full Text] [Related]
15. [New breakthrough in type 2 diabetic mellitus with chronic kidney disease: nonsteroidal, highly selective mineralocorticoid receptor antagonist]. Li H Zhonghua Nei Ke Za Zhi; 2021 Jan; 60(1):5-8. PubMed ID: 33397014 [TBL] [Abstract][Full Text] [Related]